Predicting liver cancer risk in chronic hepatitis B
Part of Cancer, Digestive system, Infections clinical trials.
This study uses patient data to build a model that predicts the chance of developing liver cancer in people with chronic hepatitis B who are on antiviral treatment. It aims to help doctors identify who might need closer monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver fibrosis or cirrhosis caused by hepatitis B.
- You are currently taking antiviral medication for hepatitis B.
- You have been followed for at least 6 months and up to 5 years.
- You have had at least two follow-up visits with your doctor.
- You have not been diagnosed with liver cancer or had a liver transplant at the start of the study or within 6 months after.
- You do not have other serious liver diseases (like fatty liver disease or drug-induced liver injury) or other cancers (except those considered cured).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether continuing antiviral therapy after surgery for hepatitis B-related liver cancer can improve outcomes. It focuses on patients with early-stage disease, good liver function, and no prior cancer treatments other than surgery or ablation.
This study looks at whether non-invasive tests can tell if liver damage is reversing in people with hepatitis B who have been on antiviral therapy for at least a year. It aims to help avoid repeated liver biopsies.
This study looks at your risk of developing liver cancer if you have hepatitis B. It uses your medical history and test results to give you a better idea of your risk and help guide next steps.
This trial uses a computer model to predict if your liver cancer might come back aggressively after surgery. If you are at high risk, you may receive additional treatment before surgery to lower that risk.
This study looks at hepatitis B “pgRNA” in blood to see if it can predict long-term outcomes in people with chronic hepatitis B who are treated with antiviral medicines. It may help doctors better forecast risk and guide follow-up over time.
This study looks at what factors predict liver cancer (HCC) in people with HCV-related cirrhosis after they've been cured of hepatitis C. It compares those who developed HCC soon after cure to those who didn't, to find clues for better monitoring.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.